UBS AM
AUPH icon

UBS AM’s Aurinia Pharmaceuticals AUPH Stock Holding History

UBS AM’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.9M Sell
229,662
-3,594
-2% -$57.4K ﹤0.01% 1727
2026
Q1 		$3.46M Buy
233,256
+232,766
+47,503% +$3.4M ﹤0.01% 1761
2025
Q4 		$7.82K Sell
490
-218,048
-100% -$3.09M ﹤0.01% 2901
2025
Q3 		$2.41M Sell
218,538
-225,040
-51% -$2.46M ﹤0.01% 1670
2025
Q2 		$3.76M Buy
443,578
+284,431
+179% +$2.28M ﹤0.01% 1840
2025
Q1 		$1.28M Sell
159,147
-204,527
-56% -$1.66M ﹤0.01% 2205
2024
Q4 		$3.27M Buy
363,674
+65,220
+22% +$532K ﹤0.01% 1814
2024
Q3 		$2.19M Sell
298,454
-27,428
-8% -$170K ﹤0.01% 1994
2024
Q2 		$1.86M Buy
325,882
+165,734
+103% +$873K ﹤0.01% 2036
2024
Q1 		$802K Hold
160,148
– – ﹤0.01% 2114
2023
Q4 		$1.44M Buy
160,148
+12,447
+8% +$103K ﹤0.01% 1835
2023
Q3 		$1.15M Sell
147,701
-955
-0.6% -$9.34K ﹤0.01% 1883
2023
Q2 		$1.63M Hold
148,656
– – ﹤0.01% 1770
2023
Q1 		$1.63M Buy
148,656
+6,277
+4% +$55.3K ﹤0.01% 1770
2022
Q4 		$615K Buy
142,379
+51,569
+57% +$299K ﹤0.01% 2093
2022
Q3 		$683K Sell
90,810
-9,030
-9% -$78.2K ﹤0.01% 2188
2022
Q2 		$1M Buy
99,840
+47,100
+89% +$527K ﹤0.01% 1961
2022
Q1 		$653K Sell
52,740
-88,719
-63% -$1.37M ﹤0.01% 2356
2021
Q4 		$1.97M Buy
141,459
+129,178
+1,052% +$3.06M ﹤0.01% 1880
2021
Q3 		$272K Sell
12,281
-129,178
-91% -$2.05M ﹤0.01% 2638
2021
Q2 		$1.84M Buy
141,459
+21,300
+18% +$271K ﹤0.01% 1894
2021
Q1 		$1.56M Buy
120,159
+8,200
+7% +$119K ﹤0.01% 1860
2020
Q4 		$1.54M Buy
111,959
+12,700
+13% +$185K ﹤0.01% 1787
2020
Q3 		$1.46M Buy
99,259
+19,900
+25% +$288K ﹤0.01% 1681
2020
Q2 		$1.28M Buy
79,359
+5,900
+8% +$94.5K ﹤0.01% 1698
2020
Q1 		$1.05M Buy
73,459
+18,200
+33% +$321K ﹤0.01% 1678
2019
Q4 		$1.12M Buy
55,259
+38,800
+236% +$357K ﹤0.01% 1853
2019
Q3 		$87.9K Buy
16,459
+3,159
+24% +$19.1K ﹤0.01% 2676
2019
Q2 		$87.9K Buy
+13,300
New +$84.8K ﹤0.01% 2657

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM's AUPH Position: Q2 2026 in Review

UBS AM reduced its Aurinia Pharmaceuticals (AUPH) stake by 1.5% in Q2 2026, selling an estimated $57.4K and leaving 229,662 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1727.

UBS AM first reported a position in AUPH in Q2 2019 and has held it in 29 quarters since. 280 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • UBS AM held 229,662 shares of Aurinia Pharmaceuticals worth $3.9M as of Q2 2026.
  • UBS AM sold 3,594 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $57.4K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1727 holding.
  • UBS AM first reported a position in Aurinia Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • 280 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.